Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

iCRT14 is a potent inhibitor of β-catenin-responsive transcription (CRT) that inhibits Wnt signaling in a reporter assay in vitro (IC50 = 40.3 nM).1 It inhibits the interaction between β-catenin and T cell factor 4 (Tcf4) in quantitative reporter assays of β-catenin/Tcf4 binding (Ki = 53.51 μM).2 It inhibits Notch, hedgehog (Hh), and JAK/STAT signaling in reporter assays with IC50 values of 69.2, 194, and 70 nM, respectively. iCRT14 (50 mg/kg, i.p.) reduces the number of proliferating cells and leads to a decrease of approximately 50% in the initial tumor growth rate in mouse xenograft models of colon carcinoma. iCRT14 also inhibits proliferation of leukemia cell lines and suppresses ATP-driven migration of the MCF-7 and MDA-MB-231 breast cancer cell lines.3,4
WARNING This product is not for human or veterinary use.
1. An RNAi-
2. Targeting the Tcf4 G13ANDE17 binding site to selectively disrupt β-
3. Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukemia. Br. J. Haematol. 167(1), 87-99 (2014).
4. ATP-